Valuation: Cipla Limited

Market Cap 1,086B 11.29B 10.03B 9.37B 8.54B 16.1B 16.25B 113B 43.92B 555B 42.4B 41.48B 1,781B P/E 2027 *
26.2x
P/E 2028 * 21.1x
Enterprise Value 980B 10.19B 9.05B 8.45B 7.7B 14.53B 14.66B 102B 39.63B 501B 38.26B 37.43B 1,607B EV / Sales 2027 *
3.16x
EV / Sales 2028 * 2.75x
Free-Float
68.87%
Yield 2027 *
0.97%
Yield 2028 * 1.1%
1 day-0.71%
1 week-4.11%
Current month-0.71%
1 month-4.76%
3 months-8.50%
6 months+9.38%
Current year-16.67%
1 week 14
Extreme 14
14.5
1 month 14
Extreme 14
14.8
Current year 12.8
Extreme 12.8
17
1 year 12.8
Extreme 12.8
18.9
3 years 12.8
Extreme 12.8
20
5 years 10.4
Extreme 10.4
20
10 years 4.94
Extreme 4.94
20
Manager TitleAgeSince
Chief Executive Officer - 01/04/2026
Director of Finance/CFO - 24/07/2026
President - 18/05/2026
Director TitleAgeSince
Chairman 90 21/07/1972
Director/Board Member 72 25/07/2014
Director/Board Member 71 30/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%-4.11% - - 11.29B
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -0.76%-3.39%+26.07%+58.90% 410.8B
Weighted average by Cap. -0.60%-3.33%+29.07%+71.15%

Financials

2027 *2028 *
Net sales 310B 3.22B 2.86B 2.67B 2.44B 4.6B 4.64B 32.35B 12.54B 158B 12.1B 11.84B 508B 347B 3.61B 3.21B 3B 2.73B 5.15B 5.2B 36.26B 14.05B 178B 13.57B 13.27B 570B
Net income 41.35B 430M 382M 357M 325M 613M 619M 4.32B 1.67B 21.14B 1.62B 1.58B 67.85B 51.42B 535M 475M 444M 404M 763M 770M 5.37B 2.08B 26.29B 2.01B 1.96B 84.37B
Net Debt -106B -1.1B -980M -915M -834M -1.57B -1.59B -11.07B -4.29B -54.23B -4.14B -4.05B -174B -131B -1.37B -1.21B -1.13B -1.03B -1.95B -1.97B -13.72B -5.32B -67.2B -5.13B -5.02B -216B
Logo Cipla Limited
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Employees
31,369
Date Price Change
01/10/26 USD 14.00 -0.71%
30/09/26 USD 14.10 -2.08%
29/09/26 USD 14.40 -0.69%
28/09/26 USD 14.50 -0.68%
25/09/26 USD 14.60 0.00%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
1,344.00INR
Average target price
1,509.08INR
Spread / Average Target
+12.28%

Quarterly revenue - Rate of surprise